Indivior PLC (LON:INDV – Get Free Report) shares traded down 15.7% during mid-day trading on Thursday . The stock traded as low as GBX 548.71 ($6.95) and last traded at GBX 732 ($9.28). 1,888,371 shares traded hands during mid-day trading, an increase of 166% from the average session volume of 709,477 shares. The stock had previously closed at GBX 868 ($11.00).
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group reissued a “buy” rating and issued a GBX 1,800 ($22.81) target price on shares of Indivior in a research note on Tuesday, December 17th.
Get Our Latest Stock Report on INDV
Indivior Stock Performance
Indivior Company Profile
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
See Also
- Five stocks we like better than Indivior
- Why Are These Companies Considered Blue Chips?
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- About the Markup Calculator
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Earnings Per Share Calculator: How to Calculate EPS
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.